

# Nicola Maurea

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8954321/nicola-maurea-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53  
papers

1,179  
citations

23  
h-index

33  
g-index

57  
ext. papers

1,482  
ext. citations

5  
avg, IF

4.04  
L-index

#	Paper	IF	Citations
53	Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 113-9	3.3	78
52	Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 130-7	12.3	69
51	Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 1240-3	4.6	66
50	Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 358-66	12.3	61
49	The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 482-9	12.3	52
48	Effects of histamine on coronary hemodynamics in humans: role of H1 and H2 receptors. <i>Journal of the American College of Cardiology</i> , <b>1987</b> , 10, 1207-13	15.1	44
47	Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	42
46	Administration of angiotensin-converting enzyme inhibitors and $\beta$ blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?. <i>Oncologist</i> , <b>2012</b> , 17, 917-24	5.7	40
45	A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17 Suppl 1, S84-92	1.9	39
44	Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 133, 511-21	4.4	38
43	Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17 Suppl 1, S19-26	1.9	37
42	Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?. <i>Human Vaccines and Immunotherapeutics</i> , <b>2016</b> , 12, 1124-31	4.4	36
41	Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. <i>Journal of Cardiovascular Medicine</i> , <b>2010</b> , 11, 861-8	1.9	36
40	Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 63, 135-143	14.4	34
39	Resveratrol in Cancer Patients: From Bench to Bedside. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	32
38	A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17 Suppl 1, S93-S104	1.9	31
37	Enhanced Drug Delivery into Cell Cytosol via Glycoprotein H-Derived Peptide Conjugated Nanoemulsions. <i>ACS Nano</i> , <b>2017</b> , 11, 9802-9813	16.7	28

36	Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial). <i>BMC Cancer</i> , <b>2014</b> , 14, 875	4.8	27
35	The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 150	8.7	27
34	Homeostasis model assessment to detect insulin resistance and identify patients at high risk of breast cancer development: National Cancer Institute of Naples experience. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2013</b> , 32, 14	12.8	25
33	Pathophysiology of anthracycline cardiotoxicity. <i>Journal of Cardiovascular Medicine</i> , <b>2016</b> , 17 Suppl 1, S3-S11	1.9	25
32	Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production. <i>Frontiers in Physiology</i> , <b>2018</b> , 9, 38	4.6	24
31	Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 2241-2250	4.4	23
30	Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. <i>BMC Cancer</i> , <b>2007</b> , 7, 50	4.8	22
29	Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. <i>Journal of Cardiovascular Medicine</i> , <b>2014</b> , 15, 141-6	1.9	21
28	Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. <i>Trials</i> , <b>2013</b> , 14, 273	2.8	19
27	Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 6785-6794	4.4	16
26	ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary. <i>European Heart Journal Supplements</i> , <b>2017</b> , 19, D370-D379	1.5	15
25	Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype. <i>Diabetology and Metabolic Syndrome</i> , <b>2014</b> , 6, 105	5.6	15
24	Circadian rhythms, adrenergic hormones and trafficking of hematopoietic stem cells. <i>Expert Opinion on Therapeutic Targets</i> , <b>2010</b> , 14, 567-75	6.4	15
23	Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	14
22	NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	14
21	Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models. <i>Journal of Personalized Medicine</i> , <b>2020</b> , 10,	3.6	14
20	Oil Core-PEG Shell Nanocarriers for In Vivo MRI Imaging. <i>Advanced Healthcare Materials</i> , <b>2019</b> , 8, e1801313.1	13.1	14
19	Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells. <i>Protein Engineering, Design and Selection</i> , <b>2014</b> , 27, 83-8	1.9	13

18	SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients. <i>Cancers</i> , <b>2020</b> , 12,	6.6	13
17	Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab. <i>International Journal of Nanomedicine</i> , <b>2020</b> , 15, 4859-4876	7.3	12
16	Boswellic acid has anti-inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells. <i>Phytotherapy Research</i> , <b>2019</b> , 33, 1670-1682	6.7	8
15	Direct coronary vasodilator effects of intracoronary histamine administration in humans. <i>Journal of Cardiovascular Pharmacology</i> , <b>1986</b> , 8, 933-9	3.1	7
14	Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports. <i>Journal of Cardiovascular Pharmacology</i> , <b>2021</b> , 78, e20-e29	3.1	6
13	Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 680758	5.3	5
12	Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with -mutated metastatic colorectal cancer: the REVOLUTION study protocol. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920929589	5.4	4
11	Intracardiac metastasis originated from chondrosarcoma. <i>Journal of Cardiovascular Medicine</i> , <b>2017</b> , 18, 385-388	1.9	3
10	Early identification of left ventricular dysfunction induced by trastuzumab. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 2698-9; author reply 2699-700	15.1	3
9	Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210330	3.7	3
8	Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature. <i>Future Oncology</i> , <b>2013</b> , 9, 127-33	3.6	1
7	Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2011</b> , 12, 636	4.1	1
6	Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 677544	5.4	1
5	Biocompatible, photo-responsive layer-by-layer polymer nanocapsules with an oil core: and study.. <i>Journal of the Royal Society Interface</i> , <b>2022</b> , 19, 20210800	4.1	0
4	The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies. <i>Antioxidants</i> , <b>2022</b> , 11, 1090	7.1	0
3	Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo. <i>Journal of Cardiovascular Echography</i> , <b>2011</b> , 21, 32-41	0.6	
2	Le alterazioni elettrocardiografiche espressione di cardiotoxicità <i>Journal of Cardiovascular Echography</i> , <b>2011</b> , 21, 55-59	0.6	
1	Management of QT Prolongation Induced by Anticancer Drugs. <i>Current Clinical Pathology</i> , <b>2019</b> , 123-132	0.1	

